Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis

Claudio Spick¹ · Hubert Bickel¹ · Stephan H. Polanec¹ · Pascal A. Baltzer¹

Received: 15 August 2017 / Revised: 6 October 2017 / Accepted: 11 October 2017 / Published online: 22 November 2017

© The Author(s) 2017. This article is an open access publication

Abstract

Purpose To investigate prevalence, malignancy rates, imaging features, and follow-up intervals for probably benign (BI-RADS 3) lesions on breast magnetic resonance imaging (MRI).

Methods A systematic database-review of articles published through 22/06/2016 was performed. Eligible studies reported BI-RADS 3 lesions on breast MRI. Two independent reviewers performed a literature review and data extraction. Data collection included study characteristics, number/type of BI-RADS 3 lesions, final diagnosis (histopathology and/or follow-up). Sources of bias (QUADAS-2) were assessed. Meta-analysis included data-pooling, heterogeneity testing, and meta-regression.

Results Fifteen studies were included. Prevalence was reported in 11 studies (range: 1.2-24.3%). Malignancy rates ranged between 0.5-10.1% (pooled 61/2814, 1.6%, 95%-CI:0.9-2.3% (random-effects-model), $I^2=53\%$, P=0.007). In a subgroup of 11 studies (2183 lesions), highest malignancy rates were observed in non-mass lesions (pooled 25/714, 2.3%, 95%-CI:0.8-3.9%, $I^2=52\%$, P=0.021) followed by mass lesions (pooled 15/771, 1.5%, 95%-CI:0.7-2.4%, $I^2=0\%$, P=0.929), and foci (pooled 10/698, 1%, 95%-CI:0.3-1.7%, $I^2=0\%$, P=0.800). There was non-significant negative association between prevalence and malignancy rates (P=0.077). Malignant lesions were diagnosed at all follow-up time points.

Conclusion While prevalence of MRI BI-RADS 3 lesions was strongly heterogeneous, pooled malignancy rates met BI-RADS benchmarks (<2%). Malignancy rates varied, exceeding 2% in non-mass lesions. Twenty-four-month surveillance is required to detect all malignant lesions.

Key points

- Probably benign (BI-RADS 3) lesions showed a pooled malignancy-rate of 1.6% (95%-CI:0.9-2.3%).
- Malignancy rates differ and are highest in non-mass lesions (2.3%, 95%-CI:0.8-3.9%).
- The prevalence of BI-RADS 3 lesions on breast MRI ranged from 1.2-24.3%.
- Malignant lesions were diagnosed at follow-up time points up to 24 months.

Keywords Breast · Magnetic resonance imaging · Meta-analysis · Diagnostic imaging · BI-RADS classification

Introduction

The Breast Imaging and Reporting Data System (BI-RADS) has been published by the American College of Radiology in order to provide a standardised description and categorisation of breast lesions on mammography, ultrasound, and magnetic resonance (MR) imaging [1].

Breast lesions classified as probably benign (BI-RADS 3) on MR imaging should have a less than two percent frequency of malignancy. These lesions should undergo short-term follow-up with an appropriate methodology to exclude malignancy, rather than being biopsied. The probably benign (BI-RADS 3) category in breast MR imaging is assigned based on the reporting radiologist’s discretion. Consequently, the resulting malignancy rates and specific imaging features of probably benign (BI-RADS 3) breast lesions on MR imaging remain a matter of debate [1].
Several studies have evaluated probably benign lesions on breast MR imaging. Investigated BI-RADS 3 characteristics included prevalence, malignancy rates, and imaging features. These studies diverged with regard to technical aspects, study populations, and reader experience. In addition, indications for MR imaging in these studies differed, ranging from high-risk screening, to problem-solving, and breast cancer staging [2, 3]. For an evidence-based approach to patient management in probably benign (BI-RADS 3) lesions on MR imaging, a systematic review and meta-analysis is warranted.

The purpose of this study was to investigate prevalence, malignancy rate, imaging features, and follow-up intervals of breast lesions assigned as probably benign (BI-RADS 3) on breast MR imaging.

Materials and Methods

This meta-analysis adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [4]. The protocol for this systematic review and meta-analysis has been prospectively registered with the PROSPERO International register of systematic reviews (registration number CRD42014013441).

Search strategy

A computerised search was performed using the Pubmed and Scopus database, including all articles listed till 22/06/2016, as no lower time-point limit was defined. The following search terms were used: “probably benign;” “BIRADS 3;” “BI-RADS 3;” “breast magnetic resonance imaging;” “breast MRI.” No language restrictions were applied. The titles and abstracts of search results were reviewed and the full text of eligible studies was retrieved. Since no specific Medical Subject Headings (MeSH) terms for this systematic literature study were identified, additional results were obtained by backward snowballing [5].

All literature searches, study selection, and data extraction were performed by two independent reviewers (CS, six years of experience in breast imaging; PAB, fourteen years of experience in breast imaging). Results after every search and analysis step were compared and discrepancies were solved in consensus. If no consensus was reached, a third reader (HB, six years of experience in breast imaging) served as an arbitrator.

Eligibility criteria for study selection

Eligibility (inclusion) criteria for study selection were as follows: peer-reviewed studies on female patients undergoing breast MR imaging in whom there were reported probably benign (BI-RADS 3) breast lesions identified by breast MR imaging. A reference standard had to be established either by histopathologic sampling or imaging follow-up of at least 12 months. Not eligible (excluded) were studies on less than 10 subjects, or review articles or studies that had investigated the use of breast MR imaging for other reasons (e.g., probably benign mammographic lesions). A study was included if data about the number and final diagnosis of BI-RADS 3 lesions assessed by magnetic resonance imaging could be extracted. No further restrictions were used.

Data collection and quality assessment

Data collection included the following parameters: publication year; study design (retrospective vs. prospective); number of observers reading MR imaging; number of patients; age; inclusion criteria for breast MR imaging; number of benign and malignant lesions; lesion size on MR imaging; lesion type (imaging features); MR imaging system type; applied field strength.

One reader applied Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) items to assess study quality and likelihood of bias. The second reader controlled the results [6]. If present, disagreement was solved in consensus.

Statistical analysis

All analyses were performed using the software programs OpenMetaAnalyst [7] and STATA 14 (Statacorp, USA). Data pooling was performed using binary random effects models with the DerSimonian-Laird method. Between-study heterogeneity was tested by $I^2$-statistics and interpreted as low ($\leq25\%$), medium ($\leq50\%$), or high ($\leq75\%$) [8]. Subgroup analyses were performed using publication year and lesion features on MR imaging (mass, non-mass, or focus) as splitting variables. Meta-regression using a random effects model was used to test for an association between the prevalence of BI-RADS 3 lesions and the respective malignancy rate of these lesions. Publication bias was assessed by Egger’s Funnel plot analysis using metaprop and confunnel commands in STATA. The metatrim command was used to calculate bias-corrected estimates according to the trim and fill method [9]. P-values $\leq0.05$ were considered significant. P-values were not adjusted for multiple comparisons.

Results

Study characteristics and risk of bias assessment

Overall, 15 eligible studies were selected (Figure 1, Figure 2, Table 1, Table 2) [10–24]. In total, 2814 lesions were included in our meta-analysis (61 showing a malignant outcome). The
prevalence of BI-RADS 3 lesions was reported in 11 studies, and ranged from 1.2-24.3% (Figure 3).

No researchers in the eligible studies applied predefined criteria for BI-RADS 3 lesions, such as a combination of specific morphological features, kinetic enhancement criteria, and clinical information (e.g., a newly diagnosed lesion), but followed the empirical guidance provided by the BI-RADS lexicon.

The study designs were described as prospective in four [10, 12, 15, 21] and retrospective in 11 studies [11, 13, 14, 16–20, 22–24]. Patient recruitment was consecutive in all included studies. Histopathology and/or follow-up was used as a reference standard in all studies. Except for one study [12], all eligible studies provided technical information on MR imaging (Table 1). However, this information was incomplete (e.g., missing spatial and temporal resolution, contrast medium, injection procedure, type of breast coil) in the majority of the studies, and four studies [15, 21, 22, 24] investigated their patients on several devices with varying protocols and field strengths (Table 1). The number of readers was not provided in three articles [12, 13, 24]. Reader experience in breast imaging was given in only six studies [11, 13, 18, 21–23], while four [16, 17, 19, 20] studies specifically reported breast MR imaging experience. The remaining studies did not report, or report insufficient details, about reader experience [10, 12, 14, 15, 24]. Inter-observer variability based on kappa analysis was not assessed in any study. Four studies were performed before 2006 [10–13] and the remaining 11 studies after 2006 [14–24]. Twelve out of 15 studies had a follow-up of 24 months or more [12–16, 18–24] while three had a shorter follow-up [10, 11, 17]. The QUADAS-2 assessment (Figure 4) revealed a low risk of bias in most examined studies. One study was assigned an unclear risk of bias with regard to the reference standard assessment due to a lack of details [12], and two studies were assigned an unclear risk of bias with regard to the conduct of the index test and test interpretation due to a lack of details [12, 24]. No concerns about the ability of the eligible studies to answer the research questions were raised (Figure 4).

**Malignancy rates in BI-RADS 3 lesions**

The general rate of malignancy was found to be highly heterogeneous (I2=53%, P=0.007, Figure 2) and ranged between 0.5–10.1% (61/2814, pooled by random effects model: 1.6%, 95%-CI: 0.9-2.3%). Studies published before 2006 showed a higher rate of malignancy (17/469, pooled by random effects model: 4.4%, 95%-CI: 0.3-8.5%, I2=70%, P=0.018, Figure 2). Studies published after 2006 showed 44/2345

---

**Fig. 2** Forest plot of malignancy rates of all studies included in the meta-analysis. Subgroup analysis demonstrates that the majority of outliers in terms of malignancy rates exceeded the BI-RADS benchmark of 2%, having been published before 2006.
| First author, year | QUADAS 2 Risk of bias | QUADAS 2 Applicability concerns | Patients | BI-RADS 3 Patients | Age (range) | Number of lesions | Number of malignant lesions | MR imaging indication | MR imaging vendor | MR imaging (Tesla) |
|--------------------|-----------------------|-------------------------------|----------|-------------------|-------------|------------------|-----------------------------|----------------------|----------------|----------------|
| Kuhl, 2000 [10]    | no                    | no                            | 192      | 44                | 38 (18-65)  | 26               | 1                           | High-Risk Screening   | Philips          | 1.5T           |
| Liberman, 2003 [11]| no                    | no                            | 367      | 89                | 50 (23-82)  | 89               | 9                           | High-Risk Screening   | GE                | 1.5T           |
| Kriege, 2004 [12]  | I* R*                 | no                            | 1909     | N/A               | 40 (19-72)  | 275              | 3                           | High-Risk Screening   | n.a.              | N/A            |
| Sadowksi, 2005 [13]| no                    | no                            | 473      | 79                | N/A (26-80) | 79               | 4                           | Problem-solving       | GE                | 1.5T           |
| Eby, 2009 [14]     | no                    | no                            | 1735     | 236               | 50 (28-80)  | 362              | 2                           | Mixed                | GE                | 1.5T           |
| Weinstein, 2010 [15]| no                    | no                            | 969      | 109               | 50 (20-85)  | 143              | 1                           | Screening contralateral breast | N/A              | 1.5T and greater |
| Hauth, 2010 [16]   | no                    | no                            | 698      | 44                | 50 (21-84)  | 56               | 1                           | Mixed, no high-risk   | Siemens           | 1.5T           |
| Marshall, 2012 [17]| no                    | no                            | 10342    | 132               | 50 (25-81)  | 132              | 2                           | Mixed                | GE and Siemens     | 1.5T           |
| Lowencco, 2014 [18]| no                    | no                            | 4370     | 345               | 49 (25-84)  | 348              | 5                           | Mixed, mainly high-risk | GE and Siemens     | 1.5T           |
| Bahrs, 2014 [19]   | no                    | no                            | N/A      | 117               | 51 (33-76)  | 163              | 3                           | Mixed                | Philips            | 1.5T           |
| Spick, 2014 [20]   | no                    | no                            | 1265     | 108               | 50 (18-89)  | 108              | 1                           | Mixed, no high-risk   | Siemens           | 1.5T           |
| Grimm, 2015 [21]   | no                    | no                            | 3131     | 265               | 50 (N/A)    | 280              | 12                          | Mixed                | GE and Siemens     | 1.5T + 3T       |
| Chikarmane, 2016 [22]| no                  | no                            | 435      | 435               | 47.2 (18-85)| 435              | 11                          | Mixed                | GE and Siemens     | 1.5T + 3T       |
| Boisserie-Lacroix, 2016 [23]| no | no                            | N/A      | 101               | N/A (23-77) | 218              | 1                           | Mixed                | Philips and Siemens | 1.5T           |
| Guillaume, 2016 [24]| I*                   | no                            | 820      | 75                | 43 (26-74)  | 100              | 5                           | Mixed, mainly high-risk | Philips and GE     | 1.5T + 3T       |
| Total              |                       |                               | 2814     | 61                |               |                  |                             |                      |                 |                |

*: denotes unclear risk of bias, I: index test, R: reference standard, N/A: information not available, GE: General Electric
malignant lesions, resulting in a pooled (random effects model) malignancy rate of 1.4%, 95%-CI: 0.7-2.1%, I²=48%, P=0.039, Figure 2. A subset of 11 studies that included 2183 lesions reported on BI-RADS 3 lesion features on MR imaging (malignancy rate 50/2183, Figure 5): the highest malignancy rate was observed in non-mass lesions (25/714, pooled by random effects model: 2.3%, 95%-CI: 0.8-3.9%, I²=52%, P=0.021), followed by mass lesions (15/771, pooled by random effects model: 1.5%, 95%-CI 0.7-2.4%, I²=52%, P=0.029), and foci (10/698, pooled by random effects model: 1%, 95%-CI 0.3-1.7%, I²=0%, P=0.800). Further lesion features, such as morphology and kinetic enhancement characteristics, were provided by only two studies [20, 21], thus precluding further systematic conclusions. There was a non-significant negative association between prevalence and malignancy rates in studies published after 2006 (P=0.077, Figure 3). Egger’s test revealed a significant publication bias (P<0.001) towards higher malignancy rates that was independent from study size (Figure 6). The bias-corrected estimate for the malignancy rate in BI-RADS 3 lesions considering 7 pseudo studies calculated by the trim and fill method (21 degrees of freedom) was 0.9%, 95%-CI: 0.1-1.7%.

Malignant diagnosis in BI-RADS 3 lesions stratified by time of diagnosis

Of the 61 malignant lesions diagnosed within the included studies, the time of diagnosis was documented in 58 of these, as one study did not provide any details ([12], Table 2). In the investigated studies, there was insufficient data given on whether six-month intervals were strictly applied and how many patients adhered to the follow-up recommendations.

Table 2 Malignant BI-RADS 3 lesions stratified by time of diagnosis

| First Author, Year | Diagnosis | Immediate | ≤6 months | ≤12 months | ≤24 months | >24 months | Total |
|-------------------|-----------|-----------|-----------|------------|------------|------------|-------|
| Kuhl, 2000 [10]   | invasive  | 0         | 1         | 0          | 0          | 0          | 1     |
|                   | non-invasive | 0         |           |            |            |            |       |
| Liberman, 2003 [11]| invasive  | 0         | N/A       | N/A        | 4          | 0          | 4     |
|                   | non-invasive | 2         | N/A       | N/A        | 3          | 0          | 5     |
| Kriege, 2004 [12]*| invasive  | N/A       | N/A       | N/A        | N/A        | N/A        | N/A   |
|                   | non-invasive | N/A       | N/A       | N/A        | N/A        | N/A        | N/A   |
| Sadowski, 2005 [13]| invasive  | 0         | 0         | 0          | 4          | 0          | 4     |
|                   | non-invasive | 0         |           |            |            |            |       |
| Eby, 2009 [14]    | invasive  | 1         | N/A       | N/A        | 1          | 0          | 2     |
|                   | non-invasive | 0         |           |            |            |            |       |
| Weinstein, 2010 [15]| invasive | 1         | N/A       | N/A        | N/A        | N/A        | N/A   |
|                   | non-invasive | 1         |           |            |            |            |       |
| Hauth, 2010 [16]  | invasive  | 0         | 1**       | 0          | 0          | 0          | 1**   |
|                   | non-invasive | 0         |           |            |            |            |       |
| Marshall, 2012 [17]| invasive  | 0         | 0         | 0          | 0          | 1          | 1     |
|                   | non-invasive | 0         | 0         | 1          | 0          | 0          | 1     |
| Lourenco, 2014 [18]| invasive  | 1         | 1         | 1          | 1          | 0          | 4     |
|                   | non-invasive | 1         | 0         | 0          | 0          | 0          | 1     |
| Bahrs, 2014 [19]  | invasive  | 0         | 0         | 1          | 0          | 0          | 1     |
|                   | non-invasive | 0         | 0         | 2          | 0          | 0          | 2     |
| Spick, 2014 [20]  | invasive  | 0         | 0         | 0          | 1          | 0          | 1     |
|                   | non-invasive | 0         |           |            |            |            |       |
| Grimm, 2015 [21]  | invasive  | 4         | 0         | 2          | 2          | 1          | 9     |
|                   | non-invasive | 1         | 0         | 0          | 1          | 1          | 3     |
| Chikarmane, 2016 [22]| invasive | 0         | 5         | 2          | 1          | 0          | 8     |
|                   | non-invasive | 0         | 2         | 0          | 1          | 0          | 3     |
| Boisserie-Lacroix, 2016 [23]| invasive | 0         | 0         | 1          | 0          | 0          | 1     |
|                   | non-invasive | 0         |           |            |            |            |       |
| Guillaume, 2016 [24]| invasive  | 1         | 2         | 1          | 0          | 0          | 4     |
|                   | non-invasive | 0         | 1         | 0          | 0          | 0          | 1     |

*: three malignant lesions without information on type or time of diagnosis; **: one phyllod malignant lesion
Of the 58 lesions, 12 (20.7%, six invasive, six non-invasive cancers) were diagnosed during the immediate work-up, such as second-look (targeted) ultrasound. Another 13 (22.4%, 10 invasive, three non-invasive cancers) were diagnosed after six months and a further 11 lesions (19.0%, eight invasive, three benign) were diagnosed after 12 months’ follow-up. Finally, 19 (32.8%, 13 invasive and six non-invasive cancers) were diagnosed within 24 months after the initial breast MR imaging, and another three lesions (5.2% 2 invasive, one non-invasive cancers) more than 24 months after the initial MR imaging scan (Table 2).

Discussion

The current systematic review and meta-analysis investigated the prevalence, malignancy rates, imaging features, and follow-up intervals of 2814 breast lesions assigned as probably benign (BI-RADS 3) on breast MR imaging. While the prevalence of MR imaging BI-RADS 3 lesions was highly variable, pooled malignancy rates for BI-RADS 3 lesions on MR imaging met BI-RADS benchmarks (<2%). Malignant lesions were diagnosed at all follow-up time points, currently underscoring the need for 24-month follow-up examinations.

Fig. 3 Meta-regression results on the influence of BI-RADS 3 prevalence on BI-RADS 3 malignancy rates (A). Removing outlier studies published before 2006 (B, see also figure 2) revealed a non-significant trend (P=0.077) of lower malignancy rates in studies that reported a higher prevalence of BI-RADS 3 lesions in their study populations. Circle diameters represent study weights according to the random effects model.

Fig. 4 QUADAS-2 graph demonstrates the risk of bias and the applicability of assessment results.
Fig. 5 Forest plot of malignancy rates from 11 studies reporting BI-RADS 3 lesion features (mass, non-mass, focus), including subgroup analysis

Fig. 6 Funnel plot of malignancy rate estimates plotted against their respective standard errors. Funnel contours reflect P-value levels. A publication bias towards higher malignancy rates that is independent from study size is evident as reflected by study points exceeding the funnel contours in the right part of the diagram. Egger’s test confirmed this bias (P<0.001)
Prevalence of MR imaging BI-RADS 3 lesions and malignancy rates of MR imaging BI-RADS 3 lesions

While the general pooled malignancy rates of BI-RADS 3 lesions on MR imaging met BI-RADS benchmarks (<2%), the rate of BI-RADS 3 compared to all examined lesions was found to be highly heterogeneous, ranging from 1.2-24.3% of all examined lesions. We explored both the heterogeneity of BI-RADS 3 prevalence and BI-RADS 3 malignancy rates and found that three of four studies published before 2006 exceeded BI-RADS benchmarks regarding malignancy rates. A minor but significant publication bias towards higher malignancy rates independent from study size was identified, as three of these studies published before 2006. Moreover, a lower threshold for calling a benign lesion BI-RADS 3 rather than BI-RADS 2, as reflected by a higher BI-RADS 3 rate, seems to be associated with a lower malignancy rate, as demonstrated in our meta-regression analysis after excluding the aforementioned outliers. These outliers may be due to data acquisition before or shortly after the first MRI BI-RADS edition or older imaging equipment. It needs to be mentioned that the three studies reporting a follow-up period of less than 2 years infer a potential bias towards higher malignancy rates. Considering the overall results reported here, this bias is rather negligible. Of note, two of these studies reported malignancy rates above the average [10, 11].

Imaging features

Malignancy rates varied according to lesion features, slightly exceeding 2% in non-mass lesions, while being below 2% in both mass and foci. One of the underlying studies revealed that eight (8.4%, 8/95) BI-RADS 3 non-mass lesions were malignant. All of these non-mass lesions presented with heterogeneous or clumped internal enhancement or showed wash-out kinetics [21]. Thus, BI-RADS 3 should be assigned only to non-mass lesions that show nonspecific benign features (e.g., focal/regional homogeneous or slightly heterogeneous enhancement) on baseline MR imaging. The same holds true for masses: lesions with suspicious features, particularly if they present with non-circumscribed or spiculated margins, are associated with a substantial risk of being malignant [25–27] and should not be classified as probably benign (BI-RADS 3).

We did not find a definite set of features that define MR imaging BI-RADS 3 lesions in the evaluated literature. Care should be taken when transferring conventional mammography and ultrasound criteria directly to breast MR imaging: despite the absence of malignant criteria, a newly diagnosed benign lesion regularly requires follow-up to exclude cancer. MR imaging however, offers functional information on tissue composition and vasculature and should thus allow the reader to assign MR imaging BI-RADS 2 in a subset of patients. Cancers that lack all three MR imaging hallmarks of malignancy (non-circumscribed or spiculated margins, plateau or wash-out curve types, and restricted diffusivity) have not been described in the current breast MR imaging literature. Thus, BI-RADS 2 may be assigned to circumscribed lesions that present with persistent enhancement [28–30]. In addition, several authors have documented that high diffusivity as measured by diffusion-weighted imaging (DWI) may reliably exclude breast cancer [31–35]. Finally, non-enhancing lesions are associated with a very low prevalence of malignancy and may thus be classified BI-RADS 2 [30]. Consequently, and by definition, MR imaging BI-RADS 3 should be assigned to lesions that fall into neither BI-RADS 2 (definitely benign) nor BI-RADS 4 (suspicious) categories. Still, a set of imaging features that define an MR imaging BI-RADS 3 lesion needs to be defined.

Clinical management and follow-up intervals in MR IMAGING BI-RADS 3 lesions

The results obtained in this systematic review and meta-analysis reveal some suggestions for the clinical management of MR imaging BI-RADS 3 lesions; a substantial rate, 12 of 58 (20.7%) malignant lesions that could be analysed in this respect, were diagnosed during the immediate work-up, including second-look ultrasound. These MR-directed ultrasound upgrades of MR imaging BI-RADS 3 [18, 21, 24] support the general application of MR-directed ultrasound in newly diagnosed MR imaging BI-RADS 3 lesions. The value of MR-directed ultrasound is underscored by a recent meta-analysis that reported a pooled discovery rate of malignant findings detected by MR imaging as high as 79% (95% CI 71-87%) [36]. The same publication revealed a pooled detection rate for benign lesions of 52% (95% CI 44-60%). As a result, a substantial rate of benign MR imaging BI-RADS 3 lesions may be identified and followed up by ultrasound [36].

Of major interest are follow-up frequencies and intervals for MR imaging BI-RADS 3 lesions. The ACR BI-RADS recommends six-month intervals over a course of 24 months, an approach adapted from conventional imaging. While a reduced number of follow-up examinations are preferable in terms of cost-effectiveness and patient compliance, our results provide supporting evidence for the current BI-RADS instructions. This is because malignant lesions were diagnosed at all time points up to 24 months after the initial diagnosis, although no study provided dedicated data on lesion appearance during each six-month imaging follow-up, and, furthermore, most authors did not specify whether six-month intervals were performed in all patients or not. This results in a research gap where dedicated data might further corroborate or refute the necessity for six-month interval follow-up over 24 months.

In conclusion, our meta-analysis identified strongly heterogeneous prevalence of MRI BI-RADS 3 lesions while pooled
malignancy rates in general met BI-RADS benchmarks (<2%). Malignancy rates varied according to lesion features, exceeding 2% in non-mass lesions. According to the lack of sufficient data, twenty-four-month surveillance is required to detect all malignant lesions.

Acknowledgement Open access funding provided by Medical University of Vienna.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is Pascal A. Baltzer.

Conflict of interest The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Funding The authors state that this work has not received any funding.

Statistics and biometry One of the authors has significant statistical expertise.

Informed consent Not applicable. All patient data reported and analysed within this meta-analysis stem from the peer-reviewed and IRB-approved primary literature.

Ethical approval Not applicable. No ethical approval needed for meta-analysis.

Methodology

• prospective
• systematic review and meta-analysis
• performed at one institution

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the creative commons license, and indicate if changes were made.

References

1. American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 5th ed. Reston, VA: American College of Radiology; 2013.
2. Comstock C, Sung JS (2013) BI-RADS 3 for magnetic resonance imaging. Magn Reson Imaging Clin N Am 21:561–570
3. Lee KA (2014) Breast Imaging Reporting and Data System category 3 for magnetic resonance imaging. Top Magn Reson Imaging TMRI 23:337–344
4. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
5. Jalali S, Wohlin C (2012) Systematic literature studies: database searches vs. backward snowballing. ACM Press, p 29
6. Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536
7. Closing the gap between methodologists and end-users: R as a computational back-end | Wallace | Journal of Statistical Software. https://www.jstatsoft.org/article/view/v049i05. Accessed 21 Nov 2016
8. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
9. Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463
10. Kuhl CK, Schmutzler RK, Leutner CC et al (2000) Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215:267–279
11. Liberman L, Morris EA, Benton CL et al (2003) Probably benign lesions at breast magnetic resonance imaging: preliminary experience in high-risk women. Cancer 98:377–388
12. Krieger V, Brekelmans CTM, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437
13. Sadowski EA, Kelcz F (2005) Frequency of malignancy in lesions classified as probably benign after dynamic contrast-enhanced breast MRI examination. J Magn Reson Imaging JMRI 21:556–564
14. Eby PR, DeMartini WB, Gutierrez RL et al (2009) Characteristics of probably benign breast MRI lesions. AJR Am J Roentgenol 193:861–867
15. Weinstein SP, Hanna LG, Gatsonis C et al (2010) Frequency of malignancy seen in probably benign lesions at contrast-enhanced breast MR imaging: findings from ACRIN 6667. Radiology 255:731–737
16. Hauth E, Umuthlu L, Kümmel S et al (2010) Follow-up of probably benign lesions (BI-RADS 3 category) in breast MR imaging. Breast J 16:297–304
17. Marshall AL, Domchek SM, Weinstein SP (2012) Follow-up frequency and compliance in women with probably benign findings on breast magnetic resonance imaging. Acad Radiol 19:406–411
18. Lourenco AP, Chung MTM, Mainiero MB (2014) Probably benign breast MRI lesions: frequency, lesion type, and rate of malignancy. J Magn Reson Imaging JMRI 39:789–794
19. Bahrs SD, Baur A, Hattermann V et al (1987) (2014) BI-RADS® 3 lesions at contrast-enhanced breast MRI: is an initial short-interval follow-up necessary? Acta Radiol Stockh Sweed 55:260–265
20. Spick C, Sozlar DHM, Baltzer PA et al (2014) Rate of malignancy in MRI-detected probably benign (BI-RADS 3) lesions. AJR Am J Roentgenol 202:684–689
21. Grimm LJ, Anderson AL, Baker JA et al (2015) Frequency of malignancy and imaging characteristics of probably benign lesions seen at breast MRI. AJR Am J Roentgenol 205:442–447
22. Chikarmane SA, Birdwell RL, Poole PS et al (2016) Characteristics, malignancy rate, and follow-up of BI-RADS category 3 lesions identified at breast MR imaging: implications for MR image interpretation and management. Radiology 280:707–715
23. Boissiere-Lacroix M, Ziadé C, Hurtvent-Labrot G et al (2016) Is a one-year follow-up an efficient method for better management of MRI BI-RADS(®) 3 lesions? Breast Edinb Scotl 27:7–17
24. Guillame R, Tiab S, Cugnart L et al (2016) BI-RADS 3 MRI lesions: Was the initial score appropriate and what is the value of the blooming sign as an additional parameter to better characterize these lesions? Eur J Radiol 85:337–345
25. Mahoney MC, Gatsonis C, Hanna L et al (2012) Positive predictive value of BI-RADS MR imaging. Radiology 264:51–58
26. Schnall MD, Blume J, Blaemke DA et al (2006) Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology 238:42–53
27. Baltzer PAT, Benndorf M, Dietzel M et al (2010) False-positive findings at contrast-enhanced breast MRI: a BI-RADS descriptor study. AJR Am J Roentgenol 194:1658–1663
28. Woitek R, Spick C, Schernthaner M, et al (2017) A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions. Eur Radiol
29. Marino MA, Clauser P, Woitek R et al (2016) A simple scoring system for breast MRI interpretation: does it compensate for reader experience? Eur Radiol 26:2529–2537
30. Baum F, Fischer U, Vossenrich R, Grabbe E (2002) Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 12:1087–1092
31. Partridge SC, Nissan N, Rahbar H et al (2017) Diffusion-weighted breast MRI: Clinical applications and emerging techniques. J Magn Reson Imaging JMRI 45:337–355
32. Pinker K, Bickel H, Helbich TH et al (2013) Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the “Breast Imaging Reporting and Data System” for multiparametric 3-T imaging of breast lesions. Eur Radiol 23:1791–1802
33. Baltzer A, Dietzel M, Kaiser CG, Baltzer PA (2016) Combined reading of contrast enhanced and diffusion weighted magnetic resonance imaging by using a simple sum score. Eur Radiol 26:884–891
34. Spick C, Pinker-Domenig K, Rudas M et al (2014) MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies. Eur Radiol 24:1204–1210
35. Woodhams R, Matsunaga K, Iwabuchi K et al (2005) Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 29:644–649
36. Spick C, Baltzer PAT (2014) Diagnostic utility of second-look US for breast lesions identified at MR imaging: systematic review and meta-analysis. Radiology 140474. doi: https://doi.org/10.1148/radiol.14140474